Benefits and risks of oral contraceptive use

References

• Physicians' Desk Reference. 46th ed. Montvale, NJ: Medical Economics Data, 1992: 310–1
   Google Scholar
• The pill: combined oral contraceptives. In: Hatcher RA, Stewart F, Trussell J, et al. Contraceptive technology: 1990–1992. New York: Irvington Publishers, 1990: 227–99
   Google Scholar
• Royal College of General Practitioners. Oral contraceptives and health: an interim report. New York: Pitman, 1974
   Google Scholar
• Murad F, Kuret JA. Estrogens and progestins. In: Gilman AG, Rail TW, Nies AS, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990: 1384–412
   Google Scholar
• Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991: 133(1): 32–7
   PubMed Web of Science ®Google Scholar
• Ramcharan S, Pellegrin FA, Ray R, et al. The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. 3. A comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. Bethesda: National Institutes of Health; 1981: NIH publication No. 81–564
   Google Scholar
• Cain MD, Walters WA, Catt KJ. Effects of oral contraceptive therapy on the reninangiotensin system. J Clin Endocrinol Metab 1971: 33(4): 671–6
   PubMed Web of Science ®Google Scholar
• Tsai CC, Williamson HO, Kirkland BH, et al. Low-dose oral contraception and blood pressure in women with a past history of elevated blood pressure. Am J Obstet Gynecol 1985: 151(1): 28–32
   PubMed Web of Science ®Google Scholar
• Ellis J. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential. Clin Ther 1986: 8(6): 607–18
   PubMed Web of Science ®Google Scholar
• Vessey MP, Lawless M, Yeates D. Oral contraceptives and stroke: findings in a large prospective study. BMJ 1984: 289(6444): 530–1
   PubMed Web of Science ®Google Scholar
• Committee on Gynecologic Practice. ACOG committee opinion. Washington, DC: American College of Obstetrics and Gynecology, 1987
   Google Scholar
• American Academy of Pediatrics. Breastfeeding and contraception. Pediatrics 1981: 68(1): 138–40
   PubMed Web of Science ®Google Scholar
• Hatcher RA, Guest F, Stewart F, et al. Lactation. In: Contraceptive technology: 1988–1989. New York: Irvington Publishers, 1989: 116–7
   Google Scholar
• Mishell DR Jr. Contraception. N Engl J Med 1989: 320(12): 777–87
   PubMed Web of Science ®Google Scholar
• Kjos SL, Shoupe D, Douyan S, et al. Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. Am J Obstet Gynecol 1990: 163(6 Pt 1): 1822–7
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990: 323(20): 1375–81
   PubMed Web of Science ®Google Scholar
• The reduction in risk of ovarian cancer associated with oral-contraceptive use: the Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987: 316(11): 650–5
   PubMed Web of Science ®Google Scholar
• Vessey M, Metcalfe A, Wells C, et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ 1987: 294(6586): 1518–20
   PubMed Web of Science ®Google Scholar
• Oral-contraceptive use and the risk of breast cancer: the Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1986: 315(7): 405–11
   PubMed Web of Science ®Google Scholar
• Lobo RA. The androgenicity of progestational agents. Int J Fertil 1988: 33(Suppl): 6–12
   PubMedGoogle Scholar
• Spona J, Huber J. Pharmacological and endocrine profiles of gestodene. Int J Fertil 1987: 32(Suppl): 6–14
   PubMedGoogle Scholar
• Bradley DD, Wingerd J, Petitti DB, et al. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978: 299(1): 17–20
   PubMed Web of Science ®Google Scholar
• Larsson-Cohn U, Fåhraeus, Wallentin L, et al. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status. Acta Obstet Gynecol Scand Suppl 1982: 105: 37–40
   PubMedGoogle Scholar
• Krauss RM, Roy S, Mishell DR Jr, et al. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses. Am J Obstet Gynecol 1983: 145(4): 446–52
   PubMed Web of Science ®Google Scholar
• Wynn V, Niththyananthan R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol 1982: 142(6 Pt 2): 766–71
   PubMed Web of Science ®Google Scholar
• Speroff L, Jones KP, Davis A. Compliance problems with OCs and HRT. Contemp Obstet Gynecol 1992: 37(Apr): 88–110
   Google Scholar
• Mishell DR Jr. Oral contraceptives for women over the age of 35. Int J Fertil 1991: 36(Suppl 2): 55–64
   PubMedGoogle Scholar
• Grimes DA. OCs and your older patient. Dialogues in Contraception 1988: 2(4): 1–3,6
   Google Scholar
• Spellacy WN, Buhi WC, Birk SA. Carbohydrate metabolism prospectively studied in women using a low-estrogen oral contraceptive for six months. Contraception 1979: 20(2): 137–48
   PubMed Web of Science ®Google Scholar
• Shoupe D, Bopp B. Contraceptive options for the gestational diabetic woman. Int J Fertil 1991: 36(Suppl 2): 80–6
   PubMedGoogle Scholar